TNFSF10 and cancer: Yet, given that TRAIL agonist receptors are generally well expressed in cancer cells, including patient biopsies, there is still hope that novel drugs, displaying the ability to restore tumor cell sensitivity to TRAIL-induced apoptosis may change the paradigm and allow the use of TRAIL in the clinic to treat patients.